ACLX News and Press, Arcellx Inc. From 08/15/22

Arcellx press release ( NASDAQ: ACLX ): Q2 GAAP EPS of -$0.88. cash, cash equivalents, and marketable securities of $307.0 million For further details see: Arcellx GAAP EPS of -$0.88

Arcellx Provides Business Highlights and Reports Second Quarter 2022 Financial Results PR Newswire -- Completed upsized follow-on offering of common stock, raising $128.8 million in gross proceeds including full exercise of underwriters' option to purchase additi...

Arcellx ( NASDAQ: ACLX ) shares are down 9% in late Wednesday afternoon trading. Today marks the end of the company's IPO lock-up period. Volume is slightly above the daily average of ~305.2K. As of 325p ET, ~401.4K shares had traded hands. Arcellx is focused on ca...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings for companies due to report...

For further details see: Arcellx named new buy at Canaccord Genuity on multiple myeloma candidate

Gainers: Greenwich LifeSciences ( GLSI ) +41% . Histogen ( HSTO ) +37% . Oramed Pharmaceuticals ( ORMP ) +25% . InMode ( INMD ) +13% . Annexon ( ANNX ) +11% . Losers: Can-Fite BioPharma ( CANF ) -11% . Arc...

At the ASCO meeting, BioNTech presented phase-1 clinical trial data for its mRNA-based vaccine for pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer. AstraZeneca and Daiichi presented data for the Destiny-Breast04 trial, which tested Enhertu against chemother...

Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares PR Newswire REDWOOD CITY, Calif. , June 21, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology com...

Gainers: Bone Biologics (BBLG) +13%. Akero Therapeutics AKRO +10%. Biotricity (BTCY) +9%. Jasper Therapeutics (JSPR) +7%. Burning Rock Biotech (BNR) +6%. Losers: AC Immune ACIU -17%. Arcellx ACLX -17%. SOPHiA GENETICS (SOPH) -16%. AirSculpt Te...

AC Immune (ACIU) -32%  as crenezumab fails in Alzheimer's study. Cango (CANG) -30%. Absci (ABSI) -14%. Hillstream BioPharma (HILS) -11%. Cepton (CPTN) -7%. Enservco Corporation (ENSV) -10%. Arcellx (ACLX) -10% on upsizing of follow-on public offering of 7M shares at $...